Search Results

Organovo Holdings, Inc. announced the pricing of a public offering consisting of 6,562,500 shares of common stock and common warrants to purchase up to an aggregate of 6,562,500 shares of its common stock, at a combined public offering price per share of common stock and accompanying common warrant to purchase one share of common stock of $0.80.

Organovo Holdings, Inc. announces it will be presenting data on the Company’s lead clinical-stage drug, FXR314 during DDW2024, which is being held in Washington, D.C. May 18-21, 2024.

Organovo Holdings, Inc. announced its intention to study combination therapy in inflammatory bowel disease and release data in calendar Q3 2024.

Organovo Holdings, Inc. today announced that it will release final and complete data from a Phase 2a trial of FXR314 in non-alcoholic steatohepatitis (NASH) patients by April 2024.

Organovo Holdings, Inc. (Nasdaq: ONVO) (Organovo) today announced that Keith Murphy, Founder and Executive Chairman, will present a corporate update and hold meetings with institutional investors during the H.C. Wainwright 25th Annual Global Investment Conference being held September 11-13, 2023.